copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC) Data on the efficacy and safety of adjuvant
Targeting ALK Rearrangements in NSCLC: Current State of the . . . Currently, six ALK-target agents have been approved to treat advanced ALK+ NSCLC, including crizotinib, alectinib, ceritinib, ensartinib, brigatinib, and lorlatinib These targeted agents induce durable responses and improve survival outcomes Treatment with ALK inhibitors is recognized as the standard of care for advanced ALK+ NSCLC
FDA Approves Alectinib for ALK-Positive Lung Cancer Alectinib targets cancer cells that have specific changes, called rearrangements, in the ALK gene The drug has been shown to increase how long people with ALK-positive metastatic NSCLC live and has become a mainstay for treatment of people with this form of lung cancer
ALK+ NSCLC Treatment Guidelines Use of ALK TKIs is effective for treatment of patients with ALK+ NSCLC and CNS involvement, and evidence supports alectinib, brigatinib or ceritinib in this setting as first-line therapy
Lorlatinib Versus Crizotinib in Patients With Advanced ALK . . . Lorlatinib improved progression-free survival (PFS) and intracranial activity versus crizotinib in patients with previously untreated, advanced, ALK -positive non–small cell lung cancer (NSCLC) in the phase III CROWN study Here, we report long-term outcomes from CROWN after 5 years of follow-up
Efficacy and Safety of Continuing Next-Generation ALK TKIs . . . Background The treatment paradigm for patients with ALK fusion–positive (ALK+) advanced or metastatic non–small cell lung cancer (NSCLC) has evolved with development of successive generations of ALK tyrosine kinase inhibitors (TKIs) Historically, patients received first-generation ALK TKI crizotinib as initial therapy, and upon disease progression, transitioned to more potent, selective
Real-world treatment sequencing and effectiveness of second . . . With multiple targeted therapies approved for anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), it is increasingly important to understand outcomes with various sequences of next-generation ALK tyrosine kinase inhibitors (TKIs) We describe contemporary sequencing patterns and treatment effectiveness of first-line (1L) and second-line (2L) treatments in
Treatment Algorithm for Advanced ALK-Rearranged NSCLC: A . . . Notably, the longest OS was observed in patients treated with crizotinib who received ALK inhibitors in subsequent treatment The aforementioned ASCEND-4 study was a randomized, phase III study that compared the second-generation ALK inhibitor, ceritinib, with chemotherapy as first-line treatment for patients with advanced ALK -rearranged NSCLC 3
Evaluating Diagnostic and Treatment Timelines for ALK . . . MicroabstractThe ALK Life Study analyzed diagnostic and treatment timelines in 1288 ALK-positive NSCLC patients from 71 countries The median time to diagnosis was 45 days, and time to TKI treatment was 30 days for advanced-stage patients Younger age, comorbidities, and geographic factors were linked to delays Outcomes may be improved by raising awareness amongst clinicians of the frequency